HANALL BIOPHARMA is a South Korean pharmaceutical company established in 1973 that develops and manufactures synthetic and biopharmaceutical products. The company's commercial portfolio includes probiotics, treatments for prostate cancer and central precocious puberty, non-absorbable antibiotics, and hair loss therapies, with key products including Biotop, Eliga, Norimix, and Hairgro. Its research and development focus targets autoimmune diseases, ocular disorders, and neurological conditions, featuring pipeline candidates such as batoclimab, aimeroferubart, tanfanercept, and HL192. HANALL BIOPHARMA operates through its subsidiary HPI, Inc. for overseas clinical trials and licensing, and maintains partnerships with Immunovant, Harbour BioMed, NurrOn Pharmaceuticals, and Daewoong Pharmaceutical for the development and commercialization of its novel therapeutics.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage hanall.com
Sector Healthcare IR page —
Tags
autoimmune diseases, ocular disorders, neurological diseases, probiotics, prostate cancer, hair loss, antibiotics, monoclonal antibodies, fcrn inhibitors, tnf inhibitors, parkinson's disease, dry eye disease, Biotop, Eliga, Norimix, Hairgro, HPI Inc., HanAll Pharmaceutical International Inc., batoclimab, HL161BKN, aimeroferubart, HL161ANS, Immunovant, Harbour BioMed, CSPC Pharmaceutical Group, NurrOn Pharmaceuticals, Daewoong Pharmaceutical, HL192, ATH-399A, tanfanercept, HL036, Turn Biotech
Press page —

Metrics

Valuation  
Market cap ₩ 2.287T
Market cap (USD) $ 1.683B
P/E -89.34
PEG —
P/BV 14.15
P/S 14.06
P/OCF -239.75
P/FCF -695.45
Dividend yield —
Turnover / mcap —
Returns  
ROE -3.4%
ROI -3.4%
ROIC -0.42%
Profit margin -3.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 155.185B 138.944B 134.91B 109.995B 101.594B 88.602B 108.452B 91.839B 84.231B 82.882B 80.023B 80.88B 74.228B
Net profit -5.559B -1.805B 3.509B 251.474M 8.896B 19.764B 19.174B 3.3B 5.813B 2.026B -7.077B -12.658B -21.499B
Free cash flow -3.288B — — — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 29.916K 34.198K — — — — — — — — — — —
Price performance 12m -0.13 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 22.7B 19.1B 17.5B 22.6B 15.7B 15.6B 30.7B 22.5B 20.1B 19.4B
↳ YoY growth -3.6% -15.7% -8.3% +29.2% -30.5% -1.1% +97.4% -26.7% -10.9% -3.6%
↳ 5y CAGR -5.6% -4.9% -7.7% -7.3% +10.0% +5.2% -2.4% +4.2%
Borrowings, current (KRW) — — — — — — — 0.00 0.00 15.7B
Borrowings, non-current (KRW) — — — — — — — 0.00 0.00 15B
Lease liabilities (KRW) — — — 568M 552M 1.34B 1.31B 1.29B 1.45B 1.18B
Cash and deposits (KRW) 9.5B 41.9B 22.7B 6.12B 4.2B 12.8B 16.8B 33.7B 16.4B 24.7B
Intangible assets (KRW) 11.7B 10.2B 5.52B 10.7B 15.1B 19.1B 23.8B 32.6B 51.8B 64.6B
Right-of-use assets (KRW) — — — 563M 539M 1.31B 1.4B 1.35B 1.5B 1.2B
Net debt (borrowings + leases - cash) (KRW) — — — — — — — -32.4B -14.9B 7.17B
Cash flow detail
Operating cash flow (KRW) 3.95B 42.1B -2.99B 20.5B 929M 840M 25.3B 29.6B 9.36B -2.34B
Purchases of property, plant and equipment (KRW) — — — — — — — -2.41B -1.64B -948M
Purchases of intangible assets (KRW) -1.04B -481M — -6.11B -4.81B -4.4B -4.77B -6.79B -18.7B -13.2B
Share buybacks (cash effect) (KRW) — — — — — — -10B 0.00 0.00 -3.22B
Interest paid (cash effect) (KRW) — — — — — — -39.5M -63.9M -71M -134M
Income taxes paid (cash effect) (KRW) -228M 66.4M -1.18B -1.91B -1.83B -1.7B -607M -1.02B -782M 215M
Free cash flow (OCF - PPE - intangibles) (KRW) — — — — — — — 20.4B -13.7B -16.5B
Income detail
Research and development expense (KRW) — — — — — — — 23.9B 20B 19.3B
Total comprehensive income (KRW) 2.24B 6.3B 5.16B 23B 39.9B -19.6B 12.8B 15.5B -19.9B -6.19B
Comprehensive income to owners (KRW) 2.24B 6.3B 5.16B 23B 39.9B -19.6B 12.8B 15.5B -19.9B -6.19B
Reported Mar 30, 2018 Mar 30, 2018 Apr 1, 2019 Mar 30, 2020 Mar 18, 2021 Mar 20, 2024 Mar 20, 2024 Mar 18, 2026 Mar 18, 2026 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

HANALL BIOPHARMA (ticker 009420), listed in South Korea.

ETFs Holding HANALL BIOPHARMA

ETF Weight in ETF Shares Market value As of
DFSE 0.01% 855 $ 32.839K Nov 12, 2026
DFAE 0.00% 9,097 $ 349.398K Nov 12, 2026
DFEM 0.00% 8,570 $ 329.157K Nov 12, 2026
DFAX 0.00% 2,936 $ 112.766K Nov 12, 2026